The food allergy market is witnessing significant momentum, with its size valued at approximately USD 3,500 million in 2025 and projected to reach nearly USD 10,500 million by 2036, growing at a CAGR of around 9% during 2026–2036. This growth reflects a broader shift within the allergy treatment market, as awareness, diagnosis rates, and therapeutic innovation continue to expand across the seven major markets (7MM) — the US, EU4 (Germany, France, Italy, Spain), the UK, and Japan.
Rising prevalence, improved diagnostic pathways, and an evolving pipeline of immunotherapies are collectively reshaping the food allergy diagnosis treatment market, moving it away from reliance on strict allergen avoidance toward proactive, disease-modifying approaches.
Key Growth Drivers
Several factors are propelling this expansion. Rising food allergy prevalence — with the 7MM reporting roughly 61 million diagnosed prevalent cases in 2025 — is a central driver, particularly among males, who accounted for 53% of gender-specific cases compared to 47% for females. Growing interest in targeted immunotherapies is also fueling opportunity within the allergy immunotherapy market, as novel treatments demonstrate improved safety and tolerability over traditional avoidance strategies.
The competitive landscape is another major catalyst. Promising pipeline candidates are advancing through clinical development, strengthening the outlook for the broader food allergy therapeutics space and supporting long-term market expansion.
Epidemiology Insights
According to epidemiological analysis, Spain recorded the highest number of diagnosed prevalent cases among the EU4 and UK, followed by Germany, while France reported the lowest. In Japan, egg allergy showed the highest diagnosed prevalence among food allergens, followed by milk allergy, with fish allergy least common — an important consideration for the egg allergy market and allergen-specific segmentation more broadly. This level of granularity supports robust food allergy epidemiology forecast modeling used to anticipate future patient burden and treatment demand.
Treatment Landscape
Management of food allergy centers on prevention, emergency preparedness, and, increasingly, long-term immune tolerance. Epinephrine remains the first-line treatment for anaphylaxis, underpinning the anaphylaxis treatment market, while antihistamines and corticosteroids serve only as adjunctive therapies.
Three approved options currently define the treatment space: omalizumab (XOLAIR), epinephrine nasal spray (NEFFY), and peanut allergen powder (PALFORZIA). XOLAIR, jointly developed by Novartis and Roche, works by targeting free IgE — a mechanism central to understanding XOLAIR MOA — and has become a key growth contributor within XOLAIR revenue discussions given its 2024 US approval for food allergy. Meanwhile, Stallergenes Greer will voluntarily discontinue PALFORZIA as of July 31, 2026, a move unrelated to safety or efficacy concerns, signaling a transition period within the peanut allergy treatment market.
Emerging immunotherapy approaches, including epicutaneous and sublingual routes, are gaining traction as safer alternatives within the hyposensitization therapy market, complementing biologics that target IgE-mediated pathways.
Pipeline and Competitive Landscape
The evolving pipeline features DBV Technologies’ Viaskin Peanut Patch (DBV712), Aravax’s PVX108 (AVX-201), and Aquestive Therapeutics’ ANAPHYLM sublingual film — each advancing distinct mechanisms of immune modulation. Notably, Aquestive received a Complete Response Letter from the FDA in January 2026 regarding ANAPHYLM, while Novartis anticipates initiating a Phase III program for remibrutinib in the second half of 2026. These developments are closely tracked within any food allergy drug pipeline analysis report, as they signal shifting competitive dynamics and future launch potential.
Regional Insights
The us food allergy diagnosis and treatment market leads globally, supported by strong regulatory frameworks, higher awareness, and early adoption of novel therapies. Within Europe, Germany held the largest 2025 market share among the EU4 and UK, followed by the UK, while France recorded the smallest share — trends relevant to the germany food allergy diagnosis treatment market, uk food allergy diagnosis treatment market, france food allergy diagnosis treatment market, and spain food allergy diagnosis treatment market. In Asia-Pacific, the japan food allergy diagnosis treatment market continues to mature alongside rising diagnostic standardization, while interest is also building around the china food allergy diagnosis treatment market as awareness and testing infrastructure improve.
Market Outlook
Looking ahead, the food allergy space is expected to see steady growth as food allergen testing market capabilities improve diagnostic accuracy, and as allergy diagnostic market infrastructure expands globally. With biologics, immunotherapies, and next-generation candidates progressing through trials, the broader allergic rhinitis market and related allergy segments are also poised for parallel innovation. Overall, differentiated therapies and rising patient awareness position the food allergy treatment market for sustained, long-term expansion through 2036.
Latest Reports Offered by Delveinsight
aesthetic implants market | alopecia market | alpha antitrypsin market | alpha-mannosidosis market | androgenetic alopecia market | anterior cruciate ligament injuries market | aplastic anemia market | arteriovenous malformations market | asperger syndrome market | atherectomy devices market | beta thalassemia market | blood purification devices market | bone neoplasms market | bone resorption market | breast biopsy market | burn market | c-met non-small cell lung cancer market | cancer vaccines market | car t cell therapy for nhl market | car t-cell therapy for non-hodgkin’s lymphoma market | cardiac monitoring system market | cardiac rhythm management devices market | cart-related neurotoxicity market | castration-resistant prostate cancer market |
About Delveinsight
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Kanishk